Detalhe da pesquisa
1.
HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients.
Kidney Int
; 99(3): 671-685, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32889013
2.
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Kidney Int
; 99(4): 986-998, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33166580
3.
Corrigendum to Berchtold L, Letouzé E, Alexander MP, et al. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney Int. 2021;99:671-685.
Kidney Int
; 100(1): 243, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34154713
4.
Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy.
Kidney Int Rep
; 8(3): 432-441, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36938074
5.
Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy.
Kidney Int Rep
; 6(6): 1677-1686, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34169209